Literature DB >> 24219004

Utilization of optimal study design for maternal and fetal sheep propofol pharmacokinetics study: a preliminary study.

Catherine M T Sherwin, Pornswan Ngamprasertwong, Senthilkumar Sadhasivam, Alexander A Vinks1.   

Abstract

Multiple blood samples are generally required for measurement of pharmacokinetic (PK) parameters. D-optimal design is a popular and frequently used approach for determination of sampling time points in order to minimize the number of samples, while optimizing the estimation of PK parameters. Optimal design utilizing ADAPT (v5, BSR, University of Southern California, Los Angeles) developed a sparse sampling strategy to determine measurement of propofol in pregnant sheep. Propofal was administered as supplemental anesthetic agent to inhalation anesthesia to mimic anesthesia for open fetal surgery. In our preliminary study, propofol 3 mg/kg was given as a bolus to the ewe, followed by propofol infusion at rate 450 mcg/kg/min for 60 minutes, then decreased to 75 mcg/kg/min for 90 more minutes and then ceased. A three compartment model described the PK parameters with the fetus assumed as the third compartment. Initially, sampling times were chosen from thirteen time points as previously stated in the literature. Using priori propofol PK estimates, the final 9 sample time points were proposed in an optimal design with a change in infusion rate occurring between 65 and 75 minutes and sampling proposed at 5, 15, 25, 65, 75, 100, 110, 150, and 180 minutes. D-optimal design optimized the number and timing of samplings, which led to a reduction of cost and man power in the study protocol while preserving the ability to estimate propofol PK parameters in the maternal and fetal sheep model. Initial evaluation of samples collected from three sheep using the optimal design strategy confirmed the performance of the design in obtaining effective PK parameter estimates.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24219004      PMCID: PMC5564389          DOI: 10.2174/1574884708666131111200417

Source DB:  PubMed          Journal:  Curr Clin Pharmacol        ISSN: 1574-8847


  14 in total

1.  Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs.

Authors:  S Retout; S Duffull; F Mentré
Journal:  Comput Methods Programs Biomed       Date:  2001-05       Impact factor: 5.428

2.  A compartmental analysis of the pharmacokinetics of propofol in sheep.

Authors:  G L Ludbrook; R N Upton; C Grant; A Martinez
Journal:  J Pharmacokinet Biopharm       Date:  1999-06

3.  Optimization of individual and population designs using Splus.

Authors:  Sylvie Retout; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

4.  Design in nonlinear mixed effects models: optimization using the Fedorov-Wynn algorithm and power of the Wald test for binary covariates.

Authors:  Sylvie Retout; Emmanuelle Comets; Adeline Samson; France Mentré
Journal:  Stat Med       Date:  2007-12-10       Impact factor: 2.373

5.  Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategy.

Authors:  A A Vinks; J W Mouton; D J Touw; H G Heijerman; M Danhof; W Bakker
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

6.  Effects of propofol and thiopental on maternal and fetal cardiovascular and acid-base variables in the pregnant ewe.

Authors:  E Alon; R H Ball; M H Gillie; J T Parer; M A Rosen; S M Shnider
Journal:  Anesthesiology       Date:  1993-03       Impact factor: 7.892

7.  Prospective evaluation of a D-optimal designed population pharmacokinetic study.

Authors:  Bruce Green; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-04       Impact factor: 2.745

8.  An evaluation of optimal sampling strategy and adaptive study design.

Authors:  G L Drusano; A Forrest; M J Snyder; M D Reed; J L Blumer
Journal:  Clin Pharmacol Ther       Date:  1988-08       Impact factor: 6.875

Review 9.  Pharmacokinetic implications for the clinical use of propofol.

Authors:  J Kanto; E Gepts
Journal:  Clin Pharmacokinet       Date:  1989-11       Impact factor: 6.447

10.  Transplacental transfer of propofol in pregnant ewes.

Authors:  A Andaluz; J Tusell; O Trasserres; C Cristòfol; B P S C Capece; M Arboix; F Garcia
Journal:  Vet J       Date:  2003-09       Impact factor: 2.688

View more
  1 in total

1.  Propofol Pharmacokinetics and Estimation of Fetal Propofol Exposure during Mid-Gestational Fetal Surgery: A Maternal-Fetal Sheep Model.

Authors:  Pornswan Ngamprasertwong; Min Dong; Jing Niu; Raja Venkatasubramanian; Alexander A Vinks; Senthilkumar Sadhasivam
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.